Literature DB >> 19226405

Hepatic steatosis is associated with low serum testosterone and high serum DHEAS levels in men.

Henry Völzke1, Nicole Aumann, Alexander Krebs, Matthias Nauck, Antje Steveling, Markus M Lerch, Dieter Rosskopf, Henri Wallaschofski.   

Abstract

Obesity and metabolic syndrome are associated with low serum testosterone levels. Hepatic steatosis contributes to the metabolic syndrome and might be regarded as its hepatic manifestation. In this study, we sought to investigate the relationship between hepatic steatosis, serum testosterone and dehydroepiandrosterone sulphate (DHEAS) levels in men. This is a cross-sectional population-based study. We used data of 1912 men recruited for the population-based Study of Health in Pomerania, which was conducted in a region with high prevalence of metabolic syndrome and related diseases. Hepatic steatosis was defined according to sonographic criteria. The relationship of hepatic steatosis with serum testosterone and DHEAS levels was analysed by multivariable logistic regression. Men with low serum testosterone levels had a higher risk of hepatic steatosis than men with high serum testosterone levels. Adjustment for age and further confounders attenuated this association, but did not affect statistical significance (odds ratio 2.36; 95% confidence interval 1.66-3.37; p < 0.05). In the full model, the highest risk of hepatic steatosis was found in subjects with the highest serum DHEAS levels (odds ratio 1.59; 95% confidence interval 1.04-2.43; p < 0.05). Exclusion of men with high alcohol consumption did not affect these results substantially. Hepatic steatosis is associated with low serum testosterone and high serum DHEAS levels. These associations are independent of alcohol consumption.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19226405     DOI: 10.1111/j.1365-2605.2009.00953.x

Source DB:  PubMed          Journal:  Int J Androl        ISSN: 0105-6263


  31 in total

1.  The likelihood of having a serum PSA level of ≥2.5 ng/mL according to the degree of fatty liver disease in a screened population.

Authors:  Jong Hyun Yoon; Hee Jo Yang; Jae Heon Kim; Seung Whan Doo; Won Jae Yang; Jiyoung Hwang; Seong Sook Hong; Suyeon Park; Dae Yeon Cho
Journal:  Can Urol Assoc J       Date:  2015-12-14       Impact factor: 1.862

Review 2.  The role of androgens in metabolism, obesity, and diabetes in males and females.

Authors:  Guadalupe Navarro; Camille Allard; Weiwei Xu; Franck Mauvais-Jarvis
Journal:  Obesity (Silver Spring)       Date:  2015-03-06       Impact factor: 5.002

Review 3.  Multicausality in fatty liver disease: is there a rationale to distinguish between alcoholic and non-alcoholic origin?

Authors:  Henry Völzke
Journal:  World J Gastroenterol       Date:  2012-07-21       Impact factor: 5.742

Review 4.  Farnesoid X receptor alpha (FXRα) is a critical actor of the development and pathologies of the male reproductive system.

Authors:  Manon Garcia; Laura Thirouard; Mélusine Monrose; Hélène Holota; Angélique De Haze; Françoise Caira; Claude Beaudoin; David H Volle
Journal:  Cell Mol Life Sci       Date:  2019-08-12       Impact factor: 9.261

5.  Study of Sex Hormone-binding Globulin Gene Polymorphism and Risk of Type 2 Diabetes Mellitus in Egyptian Men.

Authors:  S A El Tarhouny; S S Zakaria; A M Abdu-Allah; K M Hadhoud; M I Mahmoud; O M Al Nozha
Journal:  West Indian Med J       Date:  2015-05-15       Impact factor: 0.171

6.  Dehydroepiandrosterone sulfate levels in Turkish obese patients.

Authors:  Senay Topsakal; Fulya Akin; Emrah Yerlikaya; Tuba Erurker; Hilmi Dogu
Journal:  Eat Weight Disord       Date:  2014-04-09       Impact factor: 4.652

7.  Testosterone replacement ameliorates nonalcoholic fatty liver disease in castrated male rats.

Authors:  L Nikolaenko; Y Jia; C Wang; M Diaz-Arjonilla; J K Yee; S W French; P Y Liu; S Laurel; C Chong; K Lee; Y Lue; W N P Lee; R S Swerdloff
Journal:  Endocrinology       Date:  2013-11-26       Impact factor: 4.736

Review 8.  Endocrine causes of nonalcoholic fatty liver disease.

Authors:  Laura Marino; François R Jornayvaz
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

9.  Downregulation of sulfotransferase expression and activity in diseased human livers.

Authors:  Emine B Yalcin; Vijay More; Karissa L Neira; Zhenqiang James Lu; Nathan J Cherrington; Angela L Slitt; Roberta S King
Journal:  Drug Metab Dispos       Date:  2013-06-17       Impact factor: 3.922

10.  Free androgen index and Irisin in polycystic ovary syndrome.

Authors:  H Li; X Xu; X Wang; X Liao; L Li; G Yang; L Gao
Journal:  J Endocrinol Invest       Date:  2015-11-19       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.